Intercept Pharmaceuticals (NASDAQ:ICPT) has filed a marketing application in Europe seeking approval of obeticholic acid (OCA) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
An advisory committee meeting has been tentatively scheduled for April 22, 2020 related to its U.S. application, necessitating an extension of the agency’s current action date of March 26, 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.